Product Description
Mechanisms of Action: Proteasome Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Lo.Li.Pharma s.r.l
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Italy
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Leiomyoma|Myofibroma
Phase 1: COVID-19|Male Breast Cancer|Triple Negative Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
DELPHYS PLUS | P3 |
Recruiting |
Myofibroma|Leiomyoma |
2025-07-01 |
66% |
DELPHYS PLUS | P3 |
Recruiting |
Myofibroma|Leiomyoma |
2025-07-01 |
66% |
DELPHYS PLUS | P3 |
Recruiting |
Myofibroma|Leiomyoma |
2025-07-01 |
66% |
DELPHYS PLUS | P3 |
Recruiting |
Myofibroma|Leiomyoma |
2025-07-01 |
66% |
Amr Ahmed | P1 |
Not yet recruiting |
Triple Negative Breast Cancer|Male Breast Cancer |
2023-12-31 |
|
ACTRN12622000284763 | P1 |
Not yet recruiting |
COVID-19 |
None |